Immunomodulation in Endometrial Cancer

被引：18

作者：

Brooks, Nicole ^{[1
]}

Pouniotis, Dodie S. ^{[1
]}

机构：

[1] RMIT Univ, Sch Med Sci, Bundoora, Vic 3083, Australia

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2009年 / 19卷 / 04期

关键词：

Endometrial cancer; Immunomodulation; Immunotherapy; SEROUS PAPILLARY CARCINOMA; TUMOR-INFILTRATING LYMPHOCYTES; AUTOLOGOUS DENDRITIC CELLS; NATURAL-KILLER RECEPTORS; HUMAN CERVICAL-CARCINOMA; CYTOTOXIC T-LYMPHOCYTES; IN-SITU HYBRIDIZATION; HER-2/NEU OVEREXPRESSION; GENE-EXPRESSION; SERUM-LEVELS;

D O I：

10.1111/IGC.0b013e3181a12f7f

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endometrial cancer is the most frequent gynecological cancer and the fourth most common cancer in women in the developed world. Over the last decade, immunotherapy has been the focus of intense investigation as a form of cancer treatment whereby the treatment initiates a host immune response ultimately eradicating the tumor. It has been suggested that in endometrial cancer and many other forms of cancer, immunosuppression poses a significant obstacle at inducing antitumor immunity by immunotherapy. This review will look at the different studies that have identified immunomodulation of T cells, cytokines and macrophages, and regulation of apoptotic and angiogenic factors in endometrial cancer patients that may contribute to the inefficiency of immunotherapy.

引用

页码：734 / 740

页数：7

共 96 条

[1] Endometrial cancer [J].

Amant, F ;

Moerman, P ;

Neven, P ;

Timmerman, D ;

Van Limbergen, E ;

Vergote, I .

LANCET, 2005, 366 (9484) :491-505

[2] High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer [J].

Bellone, S ;

Watts, K ;

Cane, S ;

Palmieri, M ;

Cannon, MJ ;

Burnett, A ;

Roman, JJ ;

Pecorelli, S ;

Santin, AD .

GYNECOLOGIC ONCOLOGY, 2005, 98 (01) :92-98

[3] The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].

Bingle, L ;

Brown, NJ ;

Lewis, CE .

JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265

[4] Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients [J].

Bosscher, JR ;

Gercel-Taylor, C ;

Watkins, CS ;

Taylor, DD .

GYNECOLOGIC ONCOLOGY, 2001, 81 (02) :138-143

[5] Natural killer cells, viruses and cancer [J].

Cerwenka, A ;

Lanier, LL .

NATURE REVIEWS IMMUNOLOGY, 2001, 1 (01) :41-49

[6] Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma [J].

Chang, WC ;

Huang, SC ;

Torng, PL ;

Chang, DY ;

Hsu, WC ;

Chiou, SH ;

Chow, SN ;

Sheu, BC .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (06) :1073-1080

[7] Current concepts of tumor-infiltrating lymphocytes in human malignancies [J].

Chiou, SH ;

Sheu, BC ;

Chang, WC ;

Huang, SC ;

Ho, HN .

JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 67 (1-2) :35-50

[8] Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray [J].

Chitale, DA ;

Jungbluth, AA ;

Marshall, DS ;

Leitao, MM ;

Hedvat, CV ;

Kolb, D ;

Spagnoli, GC ;

Iversen, K ;

Soslow, RA .

MODERN PATHOLOGY, 2005, 18 (01) :119-126

[9] Serum levels of interleukins, growth factors and anglogenin in patients with endometrial cancer [J].

Vimlarani Chopra ;

Tung V. Ding ;

Edward V. Hanningan .

Journal of Cancer Research and Clinical Oncology, 1997, 123 (3) :167-172

[10] Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis [J].

Condeelis, J ;

Pollard, JW .

CELL, 2006, 124 (02) :263-266

← 1 2 3 4 5 6 7 8 9 10 →